gigyf2 Antibody

What is GIGYF2 and what cellular functions does it perform?

GIGYF2 is a GRB10-interacting protein that plays critical roles in translational regulation. It functions primarily in inhibiting translation initiation of defective mRNAs through a negative feedback mechanism . GIGYF2 forms a complex with 4EHP (also known as EIF4E2) and the ribosome collision sensor ZNF598, which has been confirmed through endogenous tagging and co-immunoprecipitation studies . This complex specifically targets mRNAs with translation issues, such as those lacking stop codons (non-stop mRNAs) or containing ribosome stalling sequences, preventing their translation and thereby protecting cells from potentially toxic protein products .

Functionally, GIGYF2 acts in parallel to the Ribosome-associated Quality Control (RQC) pathway, which degrades nascent polypeptides resulting from stalled ribosomes. While the RQC pathway handles the incomplete protein products, GIGYF2 and 4EHP prevent further translation initiation on problematic mRNAs .

What is the molecular weight of GIGYF2 and how is it best detected on Western blots?

GIGYF2 has a calculated molecular weight of approximately 152 kDa (1320 amino acids), but it is typically observed at 150-170 kDa on Western blots . Some antibodies detect it around 180 kDa . This minor discrepancy between calculated and observed molecular weights is not uncommon for large proteins due to post-translational modifications or protein structure affecting migration patterns.

For optimal Western blot detection, antibodies at dilutions of 1:1000 to 1:10000 are recommended, with 1:2000 being a common starting point . GIGYF2 has been successfully detected in various cell lines including HeLa, Jurkat, and NIH/3T3 cells .

What applications are GIGYF2 antibodies validated for in research settings?

GIGYF2 antibodies have been validated for multiple applications:

Many GIGYF2 antibodies have been cited in publications for knockdown/knockout validation, further confirming their specificity and utility in research settings .

How does GIGYF2 interact with 4EHP to inhibit translation of defective mRNAs?

GIGYF2 partners with 4EHP (EIF4E2), an ortholog of the mRNA cap-binding translation initiation factor EIF4E1, to inhibit translation. The mechanism involves a specialized inhibitory pathway: while 4EHP can bind to the mRNA cap structure similarly to EIF4E1, it cannot bind to EIF4G, thereby blocking the assembly of productive EIF4F initiation complexes . This effectively represses translation of the bound mRNA.

Research has demonstrated that the recruitment of either GIGYF2 or 4EHP to reporter messages blocks translation initiation . In ribosome profiling experiments, knockdown of either GIGYF2 or 4EHP increased the translation efficiency of non-stop reporter mRNAs with minimal changes in mRNA expression levels, confirming their role in translational repression rather than mRNA degradation in mammalian systems .

For experimental investigation of this interaction, co-immunoprecipitation followed by Western blotting can be performed using antibodies against both proteins (dilution 1:50 for IP is recommended) . Translation efficiency can be measured using reporter constructs with and without stalling sequences, comparing wild-type and knockdown conditions.

What is the relationship between GIGYF2, ZNF598, and the ribosome-associated quality control pathway?

GIGYF2, 4EHP, and ZNF598 form a functional network that works in parallel to the canonical Ribosome-associated Quality Control (RQC) pathway. This has been demonstrated through genetic interaction screens showing synergistic growth defects when GIGYF2 or 4EHP is knocked down in combination with NEMF (a key RQC component) .

The current model suggests that ZNF598, which acts as a ribosome collision sensor, recruits GIGYF2 and 4EHP to mRNAs with stalled ribosomes. This recruitment leads to translational silencing of the problematic mRNA, complementing the RQC-mediated degradation of the stalled nascent polypeptide . The relationship is supported by evidence that:

• GIGYF2 co-immunoprecipitates with ZNF598 endogenously

• FLAG-tagged ZNF598 immunoprecipitation enriches for GIGYF2 and 4EHP, as confirmed by mass spectrometry

• Knockdown of ZNF598 leads to increased expression of non-stop reporters but not no-go reporters, suggesting substrate-specific recruitment mechanisms

When studying this relationship experimentally, it's valuable to employ dual-fluorescent reporter systems (stalling vs. non-stalling) and examine the effects of individual and combined knockdowns of pathway components. Proteasome inhibitors like bortezomib can help distinguish between effects on translation initiation and nascent chain degradation .

What are the optimal conditions for immunoprecipitating GIGYF2 and its binding partners?

For successful immunoprecipitation of GIGYF2 and its interaction partners, consider the following protocol guidelines:

• Antibody selection: Use antibodies specifically validated for IP applications. The recommended amount is 0.5-4.0 μg of antibody for 1.0-3.0 mg of total protein lysate .

• Cell type selection: Jurkat cells have been validated for GIGYF2 immunoprecipitation , though other cell types expressing GIGYF2 may also be suitable based on your research focus.

• Lysis conditions: Use a lysis buffer that preserves protein-protein interactions. For GIGYF2 complexes with ZNF598 and 4EHP, a buffer containing:

  • 50 mM Tris-HCl (pH 7.5)

  • 150 mM NaCl

  • 1% NP-40 or Triton X-100

  • Protease inhibitor cocktail

  • Phosphatase inhibitors (if phosphorylation status is important)

• Co-IP validation: Western blotting should be performed using antibodies against suspected binding partners (ZNF598, 4EHP) at dilutions of 1:1000-1:2000 .

• Controls: Include IgG controls and, if available, lysates from GIGYF2 knockout/knockdown cells to confirm specificity.

For mass spectrometry analysis of interaction partners, FLAG-tagged constructs of GIGYF2 have proven effective in identifying novel binding partners .

How can I verify GIGYF2 antibody specificity in knockout/knockdown experiments?

Verifying antibody specificity through knockout or knockdown experiments is critical for research rigor. For GIGYF2, multiple publications have utilized this approach . A comprehensive validation protocol includes:

• Generate knockdown/knockout cells:

  • siRNA or shRNA targeting GIGYF2 for transient or stable knockdown

  • CRISPR-Cas9 for complete knockout

• Western blot validation:

  • Run control and KD/KO samples side by side

  • Use recommended antibody dilution (1:1000-1:2000)

  • Look for significant reduction or disappearance of the 150-170 kDa band

  • Include loading controls (β-actin, GAPDH)

• Functional validation:

  • Use reporter assays to measure translation of non-stop or no-go mRNAs

  • Fluorescent reporter systems with RFP/GFP ratios have proven effective

  • Confirm that GIGYF2 knockdown increases reporter expression without affecting mRNA levels

• Rescue experiments:

  • Reintroduce wild-type GIGYF2 in knockout cells

  • Confirm restoration of normal reporter expression patterns

  • This confirms that observed phenotypes are specifically due to GIGYF2 loss

Multiple publications have demonstrated that GIGYF2 knockdown increases translation efficiency of reporter constructs containing ribosome stalling sequences, providing a functional readout to confirm antibody specificity .

How do species differences affect GIGYF2 antibody selection and experimental design?

When selecting GIGYF2 antibodies for cross-species studies, several factors must be considered:

• Documented reactivity: Available antibodies show validated reactivity with human and mouse GIGYF2 . Some antibodies may cross-react with additional species including dog, rat, rabbit, and pig, particularly those targeting conserved regions .

• Epitope conservation: Antibodies targeting different regions show different cross-reactivity profiles:

  • Antibodies against AA 835-869 (central region) show human reactivity

  • Antibodies against the N-terminal region may have broader cross-reactivity

• Molecular weight variations: When working across species, slight variations in molecular weight may be observed due to species-specific isoforms or post-translational modifications.

• Functional conservation: While the GIGYF2/4EHP pathway appears functionally conserved from yeast to mammals, the yeast homologs (Smy2p and Syh1p) show some mechanistic differences, including mRNA stabilization effects that aren't observed in mammalian systems .

For comparative studies, it's advisable to validate antibody reactivity in each species of interest using positive controls and to optimize protocols accordingly.

What are the key considerations when using GIGYF2 antibodies in translation regulation studies?

When investigating GIGYF2's role in translation regulation, consider these experimental design elements:

• Reporter system selection:

  • Dual-fluorescent reporter systems using different stalling mechanisms (non-stop, no-go) allow comparative analysis

  • Include non-stalling controls expressed from separate mRNAs to monitor global translation effects

• Distinguishing translation effects from mRNA stability:

  • Quantify mRNA levels by qPCR in parallel with protein measurements

  • In mammalian systems, GIGYF2 knockdown typically increases protein without affecting mRNA levels of reporter constructs

  • In yeast, deletion of homologs (Smy2p and Syh1p) leads to mRNA stabilization, indicating potential species differences

• Ribosome profiling considerations:

  • GIGYF2/4EHP knockdown increases translation efficiency of problem mRNAs with minimal effect on endogenous messages

  • For successful ribosome profiling, ensure sufficient sequencing depth to detect effects on low-abundance reporter mRNAs

• Controls for global translation effects:

  • Monitor non-stalling control reporters expressed from separate mRNAs

  • Validate that observed effects are specific to problematic mRNAs rather than global translation changes

• Antibody applications:

  • Western blotting (1:1000-1:2000) for detecting GIGYF2 expression levels

  • Immunofluorescence (1:50-1:500) for visualizing subcellular localization

  • Co-immunoprecipitation for identifying interaction partners involved in translation regulation

How can I optimize GIGYF2 antibody-based detection in different cellular compartments?

GIGYF2 functions in translation regulation, which occurs in different cellular compartments. Optimizing detection across these compartments requires specific approaches:

• Immunofluorescence optimization:

  • Recommended dilution range: 1:50-1:500

  • Fixation method: 4% paraformaldehyde is suitable for most applications

  • Permeabilization: 0.1-0.5% Triton X-100 allows antibody access while preserving cellular structures

  • Blocking: 5% BSA or normal serum from the secondary antibody host species

  • Co-staining with markers for different cellular compartments:

    • Ribosomal markers (e.g., RPL7) to study association with ribosomes

    • P-body markers (e.g., DCP1) to examine potential localization to mRNA decay sites

• Subcellular fractionation for Western blotting:

  • Separate cytoplasmic, nuclear, membrane, and ribosome-associated fractions

  • Use compartment-specific markers to confirm fraction purity

  • Load equal protein amounts from each fraction

  • Use recommended Western blot dilutions (1:1000-1:2000)

• Stimulus-dependent localization:

  • Examine GIGYF2 localization under stress conditions that affect translation

  • Treatment with translation inhibitors (cycloheximide, puromycin) may alter localization

  • Arsenite treatment to induce stress granule formation

• Co-localization studies:

  • With ZNF598 to examine ribosome collision sites

  • With 4EHP to confirm complex formation in situ

  • With markers of translational machinery

These approaches will help determine whether GIGYF2 is uniformly distributed or concentrated at specific subcellular sites according to cellular state and experimental conditions.

What are common troubleshooting approaches for GIGYF2 antibody-based experiments?

When working with GIGYF2 antibodies, researchers may encounter several challenges. Here are solutions to common issues:

• Weak or no signal in Western blotting:

  • Increase antibody concentration (try 1:1000 if 1:2000 doesn't work)

  • Extend primary antibody incubation (overnight at 4°C)

  • Use enhanced chemiluminescence (ECL) detection systems with higher sensitivity

  • Increase protein loading (50-100 μg total protein)

  • Verify GIGYF2 expression in your cell type; HeLa and Jurkat cells are confirmed to express detectable levels

• Multiple bands or non-specific binding:

  • Increase blocking stringency (5% BSA or milk)

  • Add 0.1% Tween-20 to washing buffer

  • Reduce primary antibody concentration

  • Use freshly prepared samples to avoid degradation products

  • Consider that the observed molecular weight range (150-180 kDa) may reflect post-translational modifications

• Immunoprecipitation challenges:

  • Optimize antibody amount (0.5-4.0 μg per 1-3 mg lysate)

  • Use protein A/G beads for rabbit antibodies

  • Pre-clear lysates to reduce non-specific binding

  • Include protease inhibitors to prevent degradation during IP

  • Cross-validation with multiple antibodies targeting different epitopes

• Immunofluorescence optimization:

  • Test different fixation methods (paraformaldehyde vs. methanol)

  • Optimize permeabilization conditions

  • Use antigen retrieval methods if necessary

  • For tissue sections, TE buffer (pH 9.0) has been recommended for antigen retrieval

How do I interpret data from experiments using GIGYF2 antibodies in different experimental systems?

Proper interpretation of GIGYF2 antibody data requires considering several experimental variables:

• Expression level variation across cell types:

  • GIGYF2 is detected in various cell lines (HeLa, Jurkat, NIH/3T3) , but expression levels may vary

  • Normalize to appropriate housekeeping genes when comparing across cell types

  • Consider tissue-specific functions when interpreting IHC results (validated in breast cancer tissue)

• Reporter system interpretation:

  • In dual-fluorescent reporter systems, calculate the ratio between test reporter and control reporter

  • Increased reporter expression upon GIGYF2 knockdown indicates its role in translation suppression

  • Verify that mRNA levels remain constant to confirm translation-level effects

• Knockout/knockdown validation:

  • Complete loss of signal in Western blot validates antibody specificity

  • Partial reduction in knockdown experiments should correlate with knockdown efficiency

  • Functional readouts (e.g., reporter expression) should show dose-dependent effects with knockdown level

• Species-specific considerations:

  • Conserved function between mammalian GIGYF2 and yeast homologs, but with mechanistic differences

  • In yeast, deletion effects include mRNA stabilization, whereas mammalian knockdown primarily affects translation without changing mRNA levels

• Interaction partner analysis:

  • Co-immunoprecipitation should be reciprocal (IP with either partner should pull down the other)

  • Consider complex stability under different lysis conditions

  • Quantitative proteomics can identify relative enrichment of interaction partners

What are the latest methodological approaches for studying GIGYF2 in translation regulation networks?

Recent advances in methodology have expanded our understanding of GIGYF2's role in translation regulation:

• Ribosome profiling techniques:

  • Allow genome-wide assessment of translation efficiency changes upon GIGYF2 manipulation

  • Can identify endogenous mRNAs regulated by GIGYF2/4EHP

  • Help distinguish between global and message-specific translation effects

  • Protocol modifications such as ribosome footprint size selection can provide information on collided vs. normal ribosomes

• Multi-reporter systems:

  • Dual-fluorescent reporters expressing both test and control proteins from separate mRNAs enable internal normalization

  • Flow cytometry analysis of these reporters allows high-throughput screening and quantification

  • Multiple stalling sequences (non-stop, no-go, CGA repeats) help define substrate specificity of GIGYF2 regulation

• CRISPR-based approaches:

  • Endogenous tagging of GIGYF2 with GFP11 or other tags allows visualization and purification of native complexes

  • Genome-wide CRISPR screens using reporter readouts can identify additional factors in the pathway

  • Inducible degradation systems permit temporal control of GIGYF2 depletion

• Proteomic analysis:

  • Mass spectrometry following immunoprecipitation of FLAG-tagged ZNF598 has identified GIGYF2 and 4EHP as interaction partners

  • Quantitative approaches can determine stoichiometry and dynamics of complex formation

  • Phosphoproteomics may reveal regulatory modifications of GIGYF2

• Combined genetic interaction approaches:

  • Simultaneous knockdown of GIGYF2 with RQC components like NEMF reveals synergistic interactions

  • Double knockouts of homologs (e.g., Smy2p and Syh1p in yeast) overcome redundancy and reveal stronger phenotypes

How can GIGYF2 antibodies be used to investigate disease-relevant mechanisms?

GIGYF2 has been implicated in several disease processes, and antibody-based approaches can help elucidate its role:

• Neurodegenerative disease research:

  • GIGYF2 has been suggested to play a role in certain neurodegenerative conditions

  • Immunohistochemistry (IHC) using specific antibodies (1:20-1:200 dilution) can examine GIGYF2 expression patterns in patient-derived tissues

  • Co-localization studies with disease-relevant proteins may reveal pathological interactions

  • Western blotting of brain tissue lysates can quantify expression level changes

• Cancer biology applications:

  • GIGYF2 antibodies have been validated in human breast cancer tissue for IHC

  • Investigation of translation regulation in cancer cells may reveal tumor-specific dependencies

  • Expression correlation with cancer progression markers using tissue microarrays

• Stress response pathway analysis:

  • Immunofluorescence studies (1:50-1:500 dilution) during cellular stress can track GIGYF2 localization

  • Co-IP experiments before and after stress treatments may identify stress-specific interaction partners

  • Western blotting to examine expression changes or post-translational modifications during stress

• Translational quality control in disease models:

  • GIGYF2/4EHP pathway may be particularly important in conditions with increased translation errors

  • Reporter systems in disease models can assess pathway functionality

  • Genetic rescue experiments using wild-type vs. mutant GIGYF2 can test causality

• Therapeutic target validation:

  • Antibody-based detection methods can confirm target engagement of compounds designed to modulate GIGYF2 function

  • Proximity ligation assays can detect changes in protein-protein interactions following treatment

  • Quantitative assessment of downstream effects on translation regulation

By combining these approaches with disease-specific models, researchers can advance understanding of GIGYF2's role in pathological processes and potentially identify new therapeutic strategies.